Bahrain - engelsk - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

jaffar pharmacy - hyaluronidase - powder for injection - 1500

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

belmedpreparaty rue - hyaluronidase - powder lyophilized for solution for i/m and s/c injection - 725iu

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

"biofarma" "pp" llc - hyaluronidase - powder for solution for injection - 64iu

Bangladesh - engelsk - DGDA (Directorate General of Drug Administration)

techno drugs ltd. - hyaluronidase - injection - 150 iu/vial

De forente arabiske emirater - engelsk - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

hyaluronidase ph.eur -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 80 mg/ml; trastuzumab 40 mg/ml;   - solution for injection - active: pertuzumab 80 mg/ml trastuzumab 40 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 60 mg/ml; trastuzumab 60 mg/ml;   - solution for injection - active: pertuzumab 60 mg/ml trastuzumab 60 mg/ml   excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - rituximab 120 mg/ml;   - solution for injection - 1400mg/11.7ml - active: rituximab 120 mg/ml   excipient: histidine histidine hydrochloride hyaluronidase methionine polysorbate 80 trehalose dihydrate water for injection - non-hodgkin's lymphoma mabthera is indicated for the treatment of patients with: · cd20 positive, previously untreated low-grade or follicular, b-cell non-hodgkin's lymphoma in combination with chemotherapy, · cd20 positive, relapsed or chemoresistant low-grade or follicular, b-cell non-hodgkin's lymphoma, · cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. mabthera is indicated for maintenance treatment of patients with cd20 positive, low grade or follicular, b-cell non-hodgkin's lymphoma.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - rituximab 1600mg;   - solution for injection - 1600mg/13.4ml - active: rituximab 1600mg   excipient: histidine histidine hydrochloride methionine polysorbate 80 trehalose dihydrate vorhyaluronidase alfa water for injection - mabthera sc 1600 mg in combination with chemotherapy is indicated for the treatment of patients with chronic lymphocytic leukaemia

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab, quantity: 1600 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc 1600 mg is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.